C
Cheryl Rockman-Greenberg
Researcher at University of Manitoba
Publications - 68
Citations - 919
Cheryl Rockman-Greenberg is an academic researcher from University of Manitoba. The author has contributed to research in topics: Hypophosphatasia & Medicine. The author has an hindex of 12, co-authored 54 publications receiving 665 citations. Previous affiliations of Cheryl Rockman-Greenberg include Boston Children's Hospital & Winnipeg Regional Health Authority.
Papers
More filters
Journal ArticleDOI
Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia
Michael P. Whyte,Michael P. Whyte,Cheryl Rockman-Greenberg,Keiichi Ozono,Richard Riese,Scott Moseley,Agustin Melian,David D. Thompson,Nick Bishop,Nick Bishop,Christine Hofmann +10 more
TL;DR: Asfotase alfa mineralizes the HPP skeleton, including the ribs, and improves respiratory function and survival in life-threatening perinatal and infantile HPP.
Journal ArticleDOI
Asfotase alfa therapy for children with hypophosphatasia.
Michael P. Whyte,Katherine L Madson,Dawn Phillips,Amy Reeves,William H. McAlister,Amy Yakimoski,Karen E. Mack,Kim Hamilton,Kori Kagan,Kenji P Fujita,David D. Thompson,Scott Moseley,Tatjana Odrljin,Cheryl Rockman-Greenberg,Cheryl Rockman-Greenberg +14 more
TL;DR: Asfotase alfa enzyme replacement therapy has substantial and sustained efficacy with a good safety profile for children suffering from HPP and no evidence emerged for clinically important ectopic calcification or treatment resistance.
Journal ArticleDOI
Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia.
Priya S. Kishnani,Cheryl Rockman-Greenberg,Frank Rauch,M. Tariq Bhatti,Scott Moseley,Andrew Denker,Eric Watsky,Michael P. Whyte,Michael P. Whyte +8 more
TL;DR: It is suggested that in adults and adolescents with pediatric-onset HPP, treatment with asfotase alfa is associated with normalization of circulating TNSALP substrate levels and improved functional abilities.
Journal ArticleDOI
Identifying Non–Duchenne Muscular Dystrophy–Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review
Michele A. Gatheridge,Jennifer M. Kwon,Jerry M. Mendell,Günter Scheuerbrandt,Stuart J. Moat,François Eyskens,Cheryl Rockman-Greenberg,Anthi Drousiotou,Robert C. Griggs +8 more
TL;DR: Screening for DMD will result in identification of other muscle diseases, and future screening protocols should include infants of both sexes and include follow-up testing algorithms to evaluate patients who do not have DMD gene mutations but may have another muscle disorder associated with elevated neonatal creatine kinase levels.
Journal ArticleDOI
Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry
Wolfgang Högler,Craig B. Langman,Hugo Gomes da Silva,Shona Fang,Agnès Linglart,Keiichi Ozono,Anna Petryk,Cheryl Rockman-Greenberg,Lothar Seefried,Priya S. Kishnani +9 more
TL;DR: The Global HPP Registry represents the largest observational study of patients withHP, capturing real world data and shows that diagnostic delay is common, reflecting limited awareness of HPP, and that HPP is associated with systemic manifestations across all ages.